ALK and neuroblastoma: The robust inhibition of NB cell lines by ATR inhibition was confirmed in a xenograft NB model, where BAY 1895344 monotherapy treatment was as effective as the third-generation ALK TKI lorlatinib in reducing tumour growth (Fig. 5).